Betting on Demographics, SWFs Plunge into Health Care
February 02, 2015
by Loch Adamson
Processing request......
Target Regions of SWF Direct Healthcare Investment, 2005-’15 (Number and Total) It was a huge day for Juno Therapeutics, a fledgling, Seattle-based biotechnology company. On December 19, amid raucous applause and a blizzard of confetti at the Nasdaq Stock Market’s MarketSite studio, overlooking New York’s Times Square, the company made its trading debut. Juno, which develops gene therapies that activate a patient’s own immune system cells to attack tumors, had priced its initial public offering at $24, and shares closed the day at $35, making it one of the hottest IPOs of the year. Though CEO Hans Bishop was on hand for the festivities, he wasn’t the biggest winner. Nor were Juno’s underwriters or even the prestigious medical institutions, including Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center, that own big stakes of the company. Instead, the $51 billion Alaska Permanent Fund, holding 34.75 percent…
Sign-up for your free account to read this article
Get Started
TRANSACTION DATA IS ONLY AVAILABLE TO SUBSCRIBERS
Sovereign Wealth Center subscribers get unlimited access to all of our fund profiles, transaction data, insight and trend reports, with the ability to download the information in your preferred format.
THIS PAGE IS NOT AVAILABLE IN YOUR SUBSCRIPTION PRODUCT
For this and other features please contact our staff.